Pinto, Navin

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 357

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Church, A. J., Corson, L., Kao, P.-C., Imamovic-Tuco, A., Kang, W., Pinto, N. R., Maese, L., Laetsch, T. W., Kim, A., Colace, S., et al. (2021) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 2